RESUMEN
Data on the impact of the recently recommended maternal pertussis vaccination are promising, but still insufficient to universalise this approach. We thus compared the epidemiological data prior to the implementation of this vaccination strategy in Argentina (2012) with the figures reported after 2012. During that 2010-2016 period, two outbreaks occurred, one in 2011 and another in 2016. In the former, the incidence was 6.9/100 000 inhabitants and the case-fatality rate 2.6%. Thereafter, a decline in incidence was detected until 2014. During 2015 and 2016 an increase in the incidence transpired, but this rise was fortunately not accompanied by one in the case fatality ratio. Indeed, in 2016 the case fatality ratio was the lowest (0.6%). Moreover, during the 2016 outbreak, the incidence (3.9/100 000 inhabitants) and the case severity detected in the most vulnerable population (infants 0-2 months) were both lower than those in 2011. Consistent with this pattern, in 2016, in the most populated province of Argentina (Buenos Aires), the case percentage with laboratory-positive results indicating a high number of symptoms (59.1% of the total cases) diminished compared with that detected in the 2011 outbreak without maternal immunisation (71.9%). Using the mathematical model of pertussis transmission we previously designed, we assessed the effect of vaccination during pregnancy on infant incidence. From comparisons between the epidemiological data made through calculations, emerged the possibility that vaccinating women during pregnancy would benefit the infants beyond age 2 months, specifically in the 2-12-month cohort.
Asunto(s)
Inmunidad Materno-Adquirida , Inmunización , Vacuna contra la Tos Ferina/uso terapéutico , Tos Ferina/epidemiología , Argentina/epidemiología , Humanos , Incidencia , Modelos Teóricos , Vacunación , Tos Ferina/microbiologíaRESUMEN
Bordetella bronchiseptica, a Gram-negative bacterium, causes chronic respiratory tract infections in a wide variety of mammalian hosts, including humans (albeit rarely). We recently designed Bordetella pertussis and Bordetella parapertussis experimental vaccines based on outer membrane vesicles (OMVs) derived from each pathogen, and we obtained protection against the respective infections in mice. Here, we demonstrated that OMVs derived from virulent-phase B. bronchiseptica (OMVBbvir+) protected mice against sublethal infections with different B. bronchiseptica strains, two isolated from farm animals and one isolated from a human patient. In all infections, we observed that the B. bronchiseptica loads were significantly reduced in the lungs of vaccinated animals; the lung-recovered CFU were decreased by ≥4 log units, compared with those detected in the lungs of nonimmunized animals (P < 0.001). In the OMVBbvir+-immunized mice, we detected IgG antibody titers against B. bronchiseptica whole-cell lysates, along with an immune serum having bacterial killing activity that both recognized B. bronchiseptica lipopolysaccharides and polypeptides such as GroEL and outer membrane protein C (OMPc) and demonstrated an essential protective capacity against B. bronchiseptica infection, as detected by passive in vivo transfer experiments. Stimulation of cultured splenocytes from immunized mice with OMVBbvir+ resulted in interleukin 5 (IL-5), gamma interferon (IFN-γ), and IL-17 production, indicating that the vesicles induced mixed Th2, Th1, and Th17 T-cell immune responses. We detected, by adoptive transfer assays, that spleen cells from OMVBbvir+-immunized mice also contributed to the observed protection against B. bronchiseptica infection. OMVs from avirulent-phase B. bronchiseptica and the resulting induced immune sera were also able to protect mice against B. bronchiseptica infection.IMPORTANCEBordetella bronchiseptica, a Gram-negative bacterium, causes chronic respiratory tract infections in a wide variety of mammalian hosts, including humans (albeit rarely). Several vaccines aimed at preventing B. bronchiseptica infection have been developed and used, but a safe effective vaccine is still needed. The significance and relevance of our research lie in the characterization of the OMVs derived from B. bronchiseptica as the source of a new experimental vaccine. We demonstrated here that our formulation based on OMVs derived from virulent-phase B. bronchiseptica (OMVBbvir+) was effective against infections caused by B. bronchiseptica isolates obtained from different hosts (farm animals and a human patient). In vitro and in vivo characterization of humoral and cellular immune responses induced by the OMVBbvir+ vaccine enabled a better understanding of the mechanism of protection necessary to control B. bronchiseptica infection. Here we also demonstrated that OMVs derived from B. bronchiseptica in the avirulent phase and the corresponding induced humoral immune response were able to protect mice from B. bronchiseptica infection. This realization provides the basis for the development of novel vaccines not only against the acute stages of the disease but also against stages of the disease or the infectious cycle in which avirulence factors could play a role.
Asunto(s)
Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/inmunología , Infecciones por Bordetella/prevención & control , Bordetella bronchiseptica/citología , Bordetella bronchiseptica/patogenicidad , Animales , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/administración & dosificación , Infecciones por Bordetella/inmunología , Infecciones por Bordetella/microbiología , Bordetella bronchiseptica/química , Bordetella bronchiseptica/inmunología , Femenino , Humanos , Inmunidad Celular , Inmunidad Humoral , Inmunización , Ratones , Ratones Endogámicos BALB C , Fenotipo , Infecciones del Sistema Respiratorio/inmunología , Infecciones del Sistema Respiratorio/microbiología , Infecciones del Sistema Respiratorio/prevención & control , Células Th17/inmunología , VirulenciaRESUMEN
BACKGROUND: As has occurred in many regions worldwide, in 2012 the incidence of pertussis increased in Perú. This epidemiologic situation has been associated with a waning vaccine-induced immunity and the adaptation of Bordetella pertussis to vaccine-induced immunity along with improved diagnostic methods. METHODS: The study comprised a total of 840 pertussis-suspected cases reported in Perú during 2012. We summarize here the distribution of pertussis cases according to age and immunization status along with the immunization-coverage rate. Laboratory diagnosis was performed by culture test and real-time polymerase-chain reaction (PCR). B. pertussis bacteria recovered from infected patients were characterized by pulsed-field gel electrophoresis (PFGE), and the DNA sequencing of the pertussis-toxin (promoter and subunit A), pertactin, and fimbriae (fim2 and fim3) genes. RESULTS: From the total pertussis-suspected cases, 191 (22.7 %) infections were confirmed by real-time PCR and 18 through cultivation of B. pertussis (2.1 %), while one infection of B. parapertussis (0.11 %) was also detected by culture. Pertussis was significantly higher in patients that had had 0-3 vaccine doses (pentavalent vaccine alone) than in those who had had 4-5 vaccine doses (pentavalent plus DwPT boosters) at 94.3 vs. 5.7 %, respectively (p < 0.00001). The relative risk (RR) for patients with 4-5 doses compared to those with fewer than 4 doses or no dose was 0.23 (95 % Confidence Interval: 0.11-0.44), while the vaccine effectiveness was 77 % and coverage 50.5 %. Genetic analysis of B. pertussis isolates from different Peruvian regions detected two clonal groups as identified by PFGE. Those two groups corresponded to the B. pertussis genotypes emerging worldwide ptxP3-ptxA1-prn2 or 9-fim3-1 and ptxP3-ptxA1-prn2 or 9-fim3-2. CONCLUSIONS: Two emerging B. pertussis genotypes similar to isolates involved in worldwide epidemics were detected in Perú. Low vaccine coverage (<50 %) and genetic divergence between the vaccine-producing strain and the local isolates could contribute to this pertussal epidemic.
Asunto(s)
Bordetella pertussis/genética , Tos Ferina/epidemiología , Tos Ferina/microbiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Proteínas de la Membrana Bacteriana Externa/genética , Bordetella pertussis/aislamiento & purificación , Bordetella pertussis/patogenicidad , Niño , Preescolar , Brotes de Enfermedades , Electroforesis en Gel de Campo Pulsado , Femenino , Genotipo , Humanos , Inmunización/estadística & datos numéricos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Toxina del Pertussis/genética , Vacuna contra la Tos Ferina/administración & dosificación , Perú/epidemiología , Reacción en Cadena en Tiempo Real de la Polimerasa , Vacunación/estadística & datos numéricos , Factores de Virulencia de Bordetella/genética , Tos Ferina/inmunología , Adulto JovenRESUMEN
For the development of a third generation of pertussis vaccine that could improve the control of the disease, it was proposed that the immune responses induced by the classic whole cell vaccine (wP) or after infection should be used as a reference point. We have recently identified a vaccine candidate based on outer membrane vesicles (OMVs) derived from the disease etiologic agent that have been shown to be safe and protective in mice model of infection. Here we characterized OMVs-mediated immunity and the safety of our new candidate. We also deepen the knowledge of the induced humoral response contribution in pertussis protection. Regarding the safety of the OMVs based vaccine (TdapOMVsBp,) the in vitro whole blood human assay here performed, showed that the low toxicity of OMVs-based vaccine previously detected in mice could be extended to human samples. Stimulation of splenocytes from immunized mice evidenced the presence of IFN-γ and IL-17-producing cells, indicated that OMVs induces both Th1 and Th17 response. Interestingly TdapOMVsBp-raised antibodies such as those induced by wP and commercial acellular vaccines (aP) which contribute to induce protection against Bordetella pertussis infection. As occurs with wP-induced antibodies, the TdapOMVsBp-induced serum antibodies efficiently opsonized B. pertussis. All the data here obtained shows that OMVs based vaccine is able to induce Th1/Th17 and Th2 mixed profile with robust humoral response involved in protection, positioning this candidate among the different possibilities to constitute the third generation of anti-pertussis vaccines.
Asunto(s)
Inmunidad Humoral , Vacuna contra la Tos Ferina/inmunología , Tos Ferina/prevención & control , Animales , Anticuerpos Antibacterianos/sangre , Bordetella pertussis , Células Cultivadas , Femenino , Humanos , Sueros Inmunes/inmunología , Interferón gamma/inmunología , Interleucina-17/inmunología , Interleucina-6/inmunología , Ratones , Ratones Endogámicos BALB C , Fagocitosis , Células RAW 264.7 , Bazo/citología , Bazo/inmunología , Células Th17/inmunología , Vacunas Acelulares/inmunologíaRESUMEN
Bordetella bronchiseptica is a Gram-negative bacterium responsible for respiratory diseases in many mammalian hosts, including humans. This pathogen has been shown as able to persist inside the host cells, even in the phagosomes that are acidified to pH 4.5-5.0 after bacterial infection. Here we evaluated the resistance of B. bronchiseptica to survive under acidic conditions. In particular we analyzed the bacterial capacity to develop the mechanism known as acid tolerance response (ATR). Our studies were mainly focused on the avirulent phase of the bacteria since this phenotypic phase was reported to be more resistant to environmental stress conditions than the virulent phase. Results from B. bronchiseptica in virulent phase were also included for comparison purposes. In fact, for B. bronchiseptica 9.73 bacteria in virulent phase we observed that the viability of bacteria does not decrease significantly when grown at pH as low as 4.5, but it is affected when the pH of the medium was equal to or less than 4.0. After acid-adaptation at pH 5.5 for several hours, the survival rate of B. bronchiseptica 9.73 at lethal pH 4.0 for 6h was increased. Interestingly, the avirulent phase mediated by the two-component BvgAS system conferred further resistance to lethal acid challenge and a marked increase in the magnitude of the expressed ATR. The ATR for this avirulent phase seems to be associated with changes in LPS and surface protein profiles. 2D-gel electrophoresis revealed at least 25 polypeptides differentially expressed, 17 of which were only expressed or over-expressed under acid conditions. Using MALDI-TOF mass spectrometry, 10 of these differentially expressed polypeptides were identified.
Asunto(s)
Bordetella bronchiseptica/fisiología , Tolerancia a Medicamentos , Adaptación Fisiológica , Bordetella bronchiseptica/efectos de los fármacos , Bordetella bronchiseptica/crecimiento & desarrollo , Bordetella bronchiseptica/patogenicidad , Concentración de Iones de Hidrógeno , Viabilidad Microbiana , Transducción de Señal , Estrés Fisiológico , Factores de Transcripción , VirulenciaRESUMEN
Pertussis is an acute vaccine-preventable respiratory disease that remains a public health problem. In an attempt to improve the control of the disease, many countries have incorporated new boosters in their vaccination schedule. Since the incorporation of these boosters is relatively recent, there are not enough data about their impact to support and/or universalize their use. Alternative strategies such as the improvement in vaccine coverage and reduction in vaccination delays, in addition to the incorporation of boosters, could be implemented. Though these strategies are not new, they have not been adequately evaluated in order to be implemented and/or prioritized. To evaluate the potential impact of these alternative strategies on pertussis incidence, we developed a methodology that involves the use of data collected from vaccination centers and an age-structured deterministic mathematical model for pertussis transmission. The results obtained show that strategies that avoid delays in vaccination have a strong impact on incidence reduction in the most vulnerable population (infants less than 1 y). In regions with high vaccination coverage (95%) the elimination of delays in the three primary doses decreases pertussis incidence in infants by approximately 20%. In regions where delays in the administration of vaccines are higher, the combined action to reduce delays and improve coverage leads to a significant improvement in disease control in infants. By repeating the calculations using different sets of parameters that describe different possible epidemiologic scenarios, we determined the robustness of our results. All the results presented highlight the importance of having high vaccine coverage and shorter delays in vaccine administration in order to reduce the impact of the disease in infants.
Asunto(s)
Esquemas de Inmunización , Modelos Teóricos , Vacuna contra la Tos Ferina/inmunología , Vacunación , Tos Ferina/prevención & control , Factores de Edad , Argentina/epidemiología , Niño , Preescolar , Humanos , Incidencia , Lactante , Vacuna contra la Tos Ferina/administración & dosificación , Población Suburbana , Población Urbana , Tos Ferina/epidemiologíaRESUMEN
The incidence of the highly infectious respiratory disease named pertussis or whooping cough has been increasing for the past two decades in different countries, as in much of the highly vaccinated world. A decrease in vaccine effectiveness over time, especially when acellular vaccines were used for primary doses and boosters, and pathogen adaptation to the immunity conferred by vaccines have been proposed as possible causes of the resurgence. The contributions of these factors are not expected to be the same in different communities, and this could lead to different epidemiological trends. In fact, differences in the magnitude and dynamics of pertussis outbreaks as well as in the distribution of notified cases by age have been reported in various regions. Using an age-structured mathematical model designed by us, we evaluated how the changes in some of the parameters that could be related to the above proposed causes of disease resurgence - vaccine effectiveness and effective transmission rates - may impact on pertussis transmission. When a linear decrease in vaccine effectiveness (VE) was assayed, a sustained increase in pertussis incidence was detected mainly in infants and children. On the other hand, when changes in effective transmission rates (ßij) were made, a dynamic effect evidenced by the presence of large peaks followed by deep valleys was detected. In this case, greater incidence in adolescents than in children was observed. These different trends in the disease dynamics due to modifications in VE or ßij were verified in 18 possible scenarios that represent different epidemiological situations. Interestingly we found that both incidence trends produced by the model and their age distribution resemble the profiles obtained from data reported in several regions. The implications of these correlations are discussed.
Asunto(s)
Enfermedades Transmisibles Emergentes/etiología , Vacuna contra la Tos Ferina/farmacología , Vacunas Acelulares/farmacología , Tos Ferina/prevención & control , Adolescente , Adulto , Distribución por Edad , Anciano , Niño , Preescolar , Enfermedades Transmisibles Emergentes/epidemiología , Enfermedades Transmisibles Emergentes/prevención & control , Humanos , Incidencia , Lactante , Recién Nacido , Persona de Mediana Edad , Modelos Biológicos , Vacuna contra la Tos Ferina/administración & dosificación , Estados Unidos/epidemiología , Vacunas Acelulares/administración & dosificación , Tos Ferina/epidemiología , Tos Ferina/transmisión , Adulto JovenRESUMEN
Bordetella parapertussis, a close related species of B. pertussis, can also cause the disease named pertussis or whooping cough. The number of cases caused by this related pathogen has risen sustained in the last years. The widely used cellular (wP) or acellular (aP) pertussis vaccines have little or no efficacy against B. parapertussis. In an effort to devise an effective acellular vaccine against B. parapertussis infection, outer membrane vesicles (OMVs) were obtained from B. parapertussis. Proteomic analysis of the resulting OMVs, designated OMVsBpp, evidenced the presence of several surface immunogens including pertactin. The characterized OMVsBpp were used in murine B. parapertussis intranasal challenge model to examine their protective capacity when administered by systemic route. Immunized BALB/c mice were challenged with sublethal doses of B. parapertussis. Significant differences between immunized animals and the negative control group were observed (p<0.001). OMVsBpp protected against B. parapertussis infection, whereas current commercial aP vaccine showed little protection against such pathogen. More interestingly, protection induced by OMVsBpp against B. pertussis was comparable to our previously designed vaccine consisting in OMVs derived from B. pertussis (OMVsBp). For these experiments we used as a positive control the current commercial aP vaccine in high dose. As expected aP offered protection against B. pertussis in mice. Altogether the results presented here showed that the OMVs from B. parapertussis are an attractive vaccine candidate to protect against whooping cough induced by B. parapertussis but also by B. pertussis.
Asunto(s)
Infecciones por Bordetella/prevención & control , Bordetella parapertussis/inmunología , Bordetella pertussis/inmunología , Exosomas/inmunología , Vacuna contra la Tos Ferina/administración & dosificación , Vacuna contra la Tos Ferina/inmunología , Animales , Proteínas Bacterianas/análisis , Infecciones por Bordetella/inmunología , Modelos Animales de Enfermedad , Exosomas/química , Femenino , Ratones , Ratones Endogámicos BALB C , Vacuna contra la Tos Ferina/aislamiento & purificación , Proteoma/análisis , Vacunas Acelulares/administración & dosificación , Vacunas Acelulares/inmunología , Vacunas Acelulares/aislamiento & purificaciónRESUMEN
The exacerbated induction of innate immune responses in airways can abrogate diverse lung infections by a phenomenon known as stimulated innate resistance (StIR). We recently demonstrated that the enhancement of innate response activation can efficiently impair Bordetella pertussis colonization in a Toll-like receptor 4 (TLR4)-dependent manner. The aim of this work was to further characterize the effect of lipopolysaccharide (LPS) on StIR and to identify the mechanisms that mediate this process. Our results showed that bacterial infection was completely abrogated in treated mice when the LPS of B. pertussis (1 µg) was added before (48 h or 24 h), after (24 h), or simultaneously with the B. pertussis challenge (10(7) CFU). Moreover, we detected that LPS completely cleared bacterial infection as soon as 2 h posttreatment. This timing suggests that the observed StIR phenomenon should be mediated by fast-acting antimicrobial mechanisms. Although neutrophil recruitment was already evident at this time point, depletion assays using an anti-GR1 antibody showed that B. pertussis clearance was achieved even in the absence of neutrophils. To evaluate the possible role of free radicals in StIR, we performed animal assays using the antioxidant N-acetyl cysteine (NAC), which is known to inactivate oxidant species. NAC administration blocked the B. pertussis clearance induced by LPS. Nitrite concentrations were also increased in the LPS-treated mice; however, the inhibition of nitric oxide synthetases did not suppress the LPS-induced bacterial clearance. Taken together, our results show that reactive oxygen species (ROS) play an essential role in the TLR4-dependent innate clearance of B. pertussis.
Asunto(s)
Infecciones por Bordetella/inmunología , Bordetella pertussis/patogenicidad , Inmunidad Innata , Especies Reactivas de Oxígeno/inmunología , Acetilcisteína/administración & dosificación , Acetilcisteína/farmacología , Animales , Carga Bacteriana , Infecciones por Bordetella/microbiología , Bordetella pertussis/efectos de los fármacos , Bordetella pertussis/inmunología , Guanidinas/farmacología , Lipopolisacáridos/inmunología , Lipopolisacáridos/farmacología , Pulmón/inmunología , Pulmón/microbiología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Nitritos/metabolismo , Factores de Tiempo , Receptor Toll-Like 4/inmunologíaRESUMEN
We describe nine patients (eight aged <1 year) clinically diagnosed with pertussis yet laboratory-confirmed with Bordetella holmesii infections, a human pathogen normally isolated from blood. Most patients reported cough and cold symptoms. No death was reported. We report B. holmesii isolation in infants with respiratory symptoms in Argentina.
Asunto(s)
Infecciones por Bordetella/diagnóstico , Bordetella/aislamiento & purificación , ADN Bacteriano/análisis , Tos Ferina/diagnóstico , Argentina , Bordetella pertussis/aislamiento & purificación , Diagnóstico Diferencial , Humanos , Lactante , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
Due to the current epidemiological situation of pertussis, several countries have implemented vaccination strategies that include a booster dose for adolescents. Since there is still no evidence showing that the adolescent booster has a positive effect on the most vulnerable group represented by infants, it is difficult to universalize the recommendation to include such reinforcement. In this work we present an age-structured compartmental deterministic model that considers the outstanding epidemiological features of the disease in order to assess the impact of the booster dose at age 11 years (Tdap booster) to infants. To this end, we performed different parameterizations of the model that represent distinct possible epidemiological scenarios. The results obtained show that the inclusion of a single Tdap dose at age 11 years significantly reduces the incidence of the disease within this age group, but has a very low impact on the risk group (0-1 year). An effort to improve the coverage of the first dose would have a much greater impact on infants. These results hold in the 18 scenarios considered, which demonstrates the robustness of these conclusions.
Asunto(s)
Inmunización Secundaria/estadística & datos numéricos , Vacuna contra la Tos Ferina/uso terapéutico , Tos Ferina/transmisión , Adolescente , Argentina/epidemiología , Niño , Humanos , Esquemas de Inmunización , Lactante , Modelos Teóricos , Tos Ferina/epidemiología , Tos Ferina/prevención & controlRESUMEN
AIM: To characterize Bordetella pertussis vaccine strains in comparison with current circulating bacteria. METHODS AND RESULTS: Genomic and proteomic analyses of Bp137 were performed in comparison with other vaccine strains used in Latin America (Bp509 and Bp10536) and with the clinical Argentinean isolate Bp106. Tohama I strain was used as reference strain. Pulse-field gel electrophoresis (PFGE) and pertussis toxin promoter (ptxP) sequence analysis revealed that Bp137 groups with Bp509 in PFGE group III and contains ptxP2 sequence. Tohama I (group II) and Bp10536 (group I) contain ptxP1 sequence, while Bp106 belongs to a different PFGE cluster and contains ptxP3. Surface protein profiles diverged in at least 24 peptide subunits among the studied strains. From these 24 differential proteins, Bp10536 shared the expression of ten proteins with Tohama I and Bp509, but only three with Bp137. In contrast, seven proteins were detected exclusively in Bp137 and Bp106. CONCLUSIONS: Bp137 showed more features in common with the clinical isolate Bp106 than the other vaccine strains here included. SIGNIFICANCE AND IMPACT OF THE STUDY: The results presented show that the old strains included in vaccines are not all equal among them. These findings together with the data of circulating bacteria should be taken into account to select the best vaccine to be included in a national immunization programme.
Asunto(s)
Bordetella pertussis/genética , Bordetella pertussis/inmunología , Vacuna contra la Tos Ferina/genética , Vacuna contra la Tos Ferina/inmunología , Bordetella pertussis/clasificación , Bordetella pertussis/aislamiento & purificación , Genotipo , Humanos , Programas de Inmunización , América Latina , Fenotipo , ProteómicaRESUMEN
Although Bordetella pertussis contains and transcribes loci encoding type III secretion system (TTSS) homologues, expression of TTSS-associated proteins has been reported only for non-laboratory-adapted Irish clinical isolates. Here we confirm such a result for clinical isolates obtained from patients treated in Argentinean hospitals. Moreover, we demonstrate that the expression of TTSS-associated proteins is independent both of the year in which the isolate was obtained and of the types of polymorphic alleles for other virulence factors but is dependent on environmental growth conditions. Interestingly, we observed that TTSS-associated protein expression is lost after successive in vitro passages but becomes operative again when bacteria come into contact with the host. This in vivo activation of TTSS expression was observed not only for clinical isolates previously adapted to the laboratory after successive in vitro passages but also for vaccine strains that did not express the system in vitro. The reversibility of TTSS expression, demonstrated by its switching off-on when the bacterium comes into contact with the host, appears to be an adaptive response of this pathogen.
Asunto(s)
Proteínas Bacterianas/genética , Sistemas de Secreción Bacterianos/genética , Bordetella pertussis/genética , Bordetella pertussis/patogenicidad , Factores de Virulencia/genética , Alelos , Animales , Proteínas Bacterianas/biosíntesis , Proteínas Bacterianas/metabolismo , Ambiente , Regulación Bacteriana de la Expresión Génica , Interacciones Huésped-Patógeno , Immunoblotting , Ratones , Ratones Endogámicos BALB C , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Factores de Virulencia/metabolismo , Tos Ferina/microbiología , Tos Ferina/patologíaRESUMEN
Pertussis es una enfermedad particularmente grave en menores de 1 año. No sólo no se ha podido erradicar pese al uso de vacunas por más de cincuenta años, sino que en la actualidad ha reemergido. En junio del 2010 se registró uno de los mayores brotes de coqueluche de los Estados Unidos, con 910 casos confirmados. En la Argentina se ha venido registrando un aumento significativo de casos de pertussis. En este trabajo se presentan datos nacionales y de nuestro hospital confirmados por cultivo y/o métodos moleculares (PCR). Durante el período 2008-2010 se registraron anualmente en nuestro país entre 600 y 1.000 casos con sintomatología compatible y en el Hospital Garrahan entre 110 y 150. La confirmación se concretó en alrededor de 24% de los casos nacionales y entre un 7% y un 36,4% en el hospital. Los datos obtenidos en los laboratorios nacionales de referencia muestran un registro actual que vuelve a alcanzar los valores del 2008, luego de un descenso en el 2009. En el Hospital Garrahan, un aumento relativo en el número de casos sospechosos no confirmados podría estar vinculados a cuadros respiratorios compatibles con pertussis producidos por otros agentes etiológicos. Más allá de las variaciones anuales se puede observar la vigencia de esta enfermedad en la Argentina. Desde el punto de vista de la prevención es importante destacar que muchos de estos niños no habían recibido el esquema de vacunación completo (la mayoría de los casos se registró en menores de 6 meses). (AU)
Pertussis is a especially severe illness in infants. The use of vaccines during more than 50 years could not eradicate this illness, that now it has reemerged. In June 2010 one of the greatest outbreaks of coqueluche was recorded in the United States, with 910 confirmed cases. In Argentina, a significant increase of pertussis cases was recorded. In the present study both national and hospital data is presented, including cases confirmed by culture and/or molecular methods (PCR). During 2008-2010 between 600 and 1,000 cases were recorded in our country, and between 110 and 150 at the Hospital Garrahan. Confirmation was done in almost 24% of national cases and between 7% and 36.4% in the hospital. Data obtained by national reference laboratories showed that cases decreased from 2007 to 2008, to regain similar numbers in 2009. In the Hospital Garrahan a relative increase of non-confirmed suspected cases could be related to respiratory syndromes due to other agents but compatible with pertussis. Beyond annual fluctuations the prevalence of this illness in Argentina can be observed. From the prevention point of view it is very important to highlight that many of these children have not received the complete vaccination scheme (most of cases have been recorded in less than 6-month-old children) (AU)
Asunto(s)
Humanos , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Argentina/epidemiología , Bordetella pertussis/aislamiento & purificación , Tos Ferina/prevención & control , Tos Ferina/epidemiología , Sistema Nacional de Vigilancia Sanitaria , Hospitales Pediátricos/estadística & datos numéricosRESUMEN
Pertussis or whooping cough is an acute, highly contagious respiratory infection, which is particularly severe in infants under one year old. In classic disease, clinical diagnosis may present no difficulties. In other cases, it requires laboratory confirmation. Generally used methods are: culture, serology and PCR. For the latter, the sample of choice is a nasopharyngeal aspirate, and the simplest method for processing these samples uses proteinase K. Although results are generally satisfactory, difficulties often arise regarding the mucosal nature of the specimens. Moreover, uncertainties exist regarding the optimal conditions for sample storage. This study evaluated various technologies for processing and storing samples. Results enabled us to select a method for optimizing sample processing, with performance comparable to commercial methods and far lower costs. The experiments designed to assess the conservation of samples enabled us to obtain valuable information to guide the referral of samples from patient care centres to laboratories where such samples are processed by molecular methods.
Asunto(s)
Bordetella pertussis/aislamiento & purificación , Fraccionamiento Celular/métodos , Técnicas de Diagnóstico Molecular , Preservación Biológica/métodos , Manejo de Especímenes/métodos , Tos Ferina/diagnóstico , Bordetella pertussis/genética , Precipitación Química , Cloroformo , Recuento de Colonia Microbiana , ADN Bacteriano/aislamiento & purificación , Electroforesis en Gel de Agar , Endopeptidasa K , Etanol , Humanos , Moco/microbiología , Nasofaringe/microbiología , Fenol , Reacción en Cadena de la Polimerasa/métodos , Poliestirenos , Polivinilos , Derivación y Consulta , Sensibilidad y Especificidad , Solventes , Manejo de Especímenes/normas , Tos Ferina/microbiologíaRESUMEN
OBJECTIVES: Pertussis continues causing significant morbidity and mortality worldwide. Although its epidemiology has been studied in many developed countries, the current pertussis situation in South America is scarcely known. This review summarizes the most important recent data concerning pertussis in a country of South America, Argentina. METHODS: CDC criteria were used for pertussis diagnosis. Proportion of pertussis cases by age, immunization status, and immunization coverage rate evaluated at the Argentinean National Pertussis Reference Centers was reported. Bordetella pertussis isolates were characterized and compared with vaccine strains. RESULTS: From 2002 to nowadays, a steady increase of pertussis cases was observed. Most of these cases correspond to patients younger than six months old that received less than three doses of vaccine. However, cases in adolescent and adults have also been detected. For this situation, which is not peculiar to Argentina, several explanations have been proposed. Among them, the inability of current vaccines to induce long-lasting immunity is the most widely accepted as a cause of pertussis resurgence. Furthermore, antigenic divergence between local clinical isolates and vaccine strains may have aggravated the effect of waning immunity. CONCLUSIONS: Pertussis is an important problem for public health in Argentina. Divergence between vaccine strains and local isolates could contribute to the described pertussis epidemiology.
Asunto(s)
Tos Ferina/epidemiología , Adolescente , Argentina/epidemiología , Bordetella pertussis/clasificación , Bordetella pertussis/aislamiento & purificación , Niño , Preescolar , Dermatoglifia del ADN , Humanos , Inmunoterapia Activa/estadística & datos numéricos , Incidencia , Lactante , Recién Nacido , Tos Ferina/diagnósticoRESUMEN
Presentamos el caso de una paciente de 15 años con Fibrosis Quística (FQ) en la cual, en dos oportunidades y con un intervalo de 2 años; se aisló Bordetella Bronchiseptica con idéntico perfil genético estudiado por electroforesis de campo pulsado. El mecanismo lesional de B. Bronchiseptica en el árbol bronquial de pacientes con FQ no esta claramente establecido, pero la habilidad de esta bacteria para inhibir la función de los leucocitos y su capacidad de adherirse a las células del epitelio bronquial explicaría su capacidad infectiva y su persistencia en el tracto respiratorio.
Asunto(s)
Adolescente , Bordetella bronchiseptica , Fibrosis QuísticaRESUMEN
Presentamos el caso de una paciente de 15 años con Fibrosis Quística (FQ) en la cual, en dos oportunidades y con un intervalo de 2 años; se aisló Bordetella Bronchiseptica con idéntico perfil genético estudiado por electroforesis de campo pulsado. El mecanismo lesional de B. Bronchiseptica en el árbol bronquial de pacientes con FQ no esta claramente establecido, pero la habilidad de esta bacteria para inhibir la función de los leucocitos y su capacidad de adherirse a las células del epitelio bronquial explicaría su capacidad infectiva y su persistencia en el tracto respiratorio.
Asunto(s)
Adolescente , Bordetella bronchiseptica , Fibrosis QuísticaRESUMEN
In Argentina, as in other countries, the number of pertussis cases has been increasing, even in highly vaccinated zones. Many reports suggest that the decline of vaccine efficacy due to antigenic shifts in the circulating Bordetella pertussis might be among the factors that contribute to pertussis re-emergence in different parts of the world. To evaluate the incidence of this factor in Argentina, we decided to characterize the circulating bacteria of an important demographic area of this country in comparison with the strain used for vaccine production. From 1997 to 2003 we collected nasopharyngeal samples from pediatric patients with signs of Bordetella infection hospitalized in the metropolitan area of Buenos Aires and La Plata, Argentina. From these samples we identified 28 B. pertussis, which were characterized by biochemical techniques, PCR, DNA fingerprint, prn and ptx genes sequencing, and lipopolysaccharides (LPS) pattern. BOX-PCR from B. pertussis isolates yielded one cluster containing 13 isolates and some smaller ones, being all fingerprints different from the vaccine strain. Differences between Argentinean circulating bacteria and the vaccine strain were also observed for the Prn and Ptx variants as well as for the LPS pattern. Moreover, this last pattern seemed to change over the years. In addition, we identified two B. bronchiseptica. The presence of this Bordetella species together with the observed differences between circulating B. pertussis and the strain used in vaccine production should be considered for the development of an improved vaccine.